Fig. 4From: Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysisKaplan-Meier survival curve for time to treatment discontinuation, OTX-101 vs. LFT. †P-value refers to the difference between treatments based on the log-rank test. LFT, lifitegrast ophthalmic solution 5%; OTX-101, cyclosporine ophthalmic solution 0.09%; TTD, time to treatment discontinuationBack to article page